ergocalciferols

Summary

Summary: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.

Top Publications

  1. ncbi Vitamin D analogues for secondary hyperparathyroidism
    Alex J Brown
    Renal Division, Washington University School of Medicine, St Louis, Missouri, USA
    Nephrol Dial Transplant 17:10-9. 2002
  2. ncbi Mortality risk among hemodialysis patients receiving different vitamin D analogs
    F Tentori
    Dialysis Clinic Inc, Albuquerque, New Mexico, USA
    Kidney Int 70:1858-65. 2006
  3. ncbi Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis
    Edward A Ross
    Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, FL 32610 0224, USA
    Am J Nephrol 28:97-106. 2008
  4. ncbi Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly
    Elisabetta Romagnoli
    Department of Clinical Sciences, University of Rome Sapienza, Viale del Policlinico 155, 00161 Rome, Italy
    J Clin Endocrinol Metab 93:3015-20. 2008
  5. ncbi Vitamin D(3) is more potent than vitamin D(2) in humans
    Robert P Heaney
    Creighton University, 601 North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA
    J Clin Endocrinol Metab 96:E447-52. 2011
  6. ncbi The case against ergocalciferol (vitamin D2) as a vitamin supplement
    Lisa A Houghton
    School of Nutrition and Dietetics, Acadia University, Wolfville, Canada
    Am J Clin Nutr 84:694-7. 2006
  7. ncbi Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults
    Rachael M Biancuzzo
    Department of Medicine, Boston University School of Medicine, MA, USA
    Am J Clin Nutr 91:1621-6. 2010
  8. ncbi Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults
    N Binkley
    Osteoporosis Clinical Center and Research Program, University of Wisconsin, Madison, Wisconsin 53705, USA
    J Clin Endocrinol Metab 96:981-8. 2011
  9. ncbi Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, PathWest Royal Perth Hospital, Perth, Western Australia 6000, Australia
    Bone 45:870-5. 2009
  10. ncbi Vitamin D2 is much less effective than vitamin D3 in humans
    Laura A G Armas
    Creighton University, 601 North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA
    J Clin Endocrinol Metab 89:5387-91. 2004

Research Grants

  1. Ergocalciferol in ESRD Efficacy Safety and Biology
    Ravi Thadhani; Fiscal Year: 2009
  2. REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY
    ISIDRO SALUSKY; Fiscal Year: 2000
  3. REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY
    Isidro B Salusky; Fiscal Year: 2004
  4. 2005 Bones & Teeth Gordon Conference
    Rene St Arnaud; Fiscal Year: 2005
  5. Evaluation of Vitamin D Requirements During Pregnancy
    Bruce Hollis; Fiscal Year: 2007
  6. Optimizing Vitamin D Treatment in HIV/AIDS: An RCT
    DOUGLAS THOMAS DIETERICH; Fiscal Year: 2010
  7. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej Slominski; Fiscal Year: 2007
  8. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej Slominski; Fiscal Year: 2009
  9. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej T Slominski; Fiscal Year: 2010
  10. Ergocalciferol in ESRD Efficacy Safety and Biology
    Ravi Thadhani; Fiscal Year: 2010

Detail Information

Publications202 found, 100 shown here

  1. ncbi Vitamin D analogues for secondary hyperparathyroidism
    Alex J Brown
    Renal Division, Washington University School of Medicine, St Louis, Missouri, USA
    Nephrol Dial Transplant 17:10-9. 2002
    ..A clear understanding of the molecular basis for the selectivity of vitamin D analogues on parathyroid function may allow the design of even more effective analogues...
  2. ncbi Mortality risk among hemodialysis patients receiving different vitamin D analogs
    F Tentori
    Dialysis Clinic Inc, Albuquerque, New Mexico, USA
    Kidney Int 70:1858-65. 2006
    ..2 (1.1-1.3)). Mortality in doxercalciferol- and paricalcitol-treated patients was virtually identical. Differences in survival between vitamin D2 and D3 may be smaller than previously reported...
  3. ncbi Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis
    Edward A Ross
    Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, FL 32610 0224, USA
    Am J Nephrol 28:97-106. 2008
    ..This study investigates the effects of oral paricalcitol to reduce PTH in patients receiving chronic HD and peritoneal dialysis (PD)...
  4. ncbi Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly
    Elisabetta Romagnoli
    Department of Clinical Sciences, University of Rome Sapienza, Viale del Policlinico 155, 00161 Rome, Italy
    J Clin Endocrinol Metab 93:3015-20. 2008
    ..In humans, few studies have compared the potencies of ergocalciferol and cholecalciferol in improving and maintaining vitamin D status...
  5. ncbi Vitamin D(3) is more potent than vitamin D(2) in humans
    Robert P Heaney
    Creighton University, 601 North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA
    J Clin Endocrinol Metab 96:E447-52. 2011
    ..Current unitage for the calciferols suggests that equimolar quantities of vitamins D(2) (D2) and D(3) (D3) are biologically equivalent. Published studies yield mixed results...
  6. ncbi The case against ergocalciferol (vitamin D2) as a vitamin supplement
    Lisa A Houghton
    School of Nutrition and Dietetics, Acadia University, Wolfville, Canada
    Am J Clin Nutr 84:694-7. 2006
    ..Vitamin D2, or ergocalciferol, should not be regarded as a nutrient suitable for supplementation or fortification...
  7. ncbi Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults
    Rachael M Biancuzzo
    Department of Medicine, Boston University School of Medicine, MA, USA
    Am J Clin Nutr 91:1621-6. 2010
    ..Vitamin D has been added to calcium-fortified orange juice. It is unknown whether vitamin D is as bioavailable from orange juice as it is from supplements...
  8. ncbi Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults
    N Binkley
    Osteoporosis Clinical Center and Research Program, University of Wisconsin, Madison, Wisconsin 53705, USA
    J Clin Endocrinol Metab 96:981-8. 2011
    ..Whether ergocalciferol (D(2)) and cholecalciferol (D(3)) are equally effective to increase and maintain serum 25-hydroxyvitamin D [25(OH)D] concentration is controversial...
  9. ncbi Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, PathWest Royal Perth Hospital, Perth, Western Australia 6000, Australia
    Bone 45:870-5. 2009
    ..However, the lack of difference in PTH lowering between calciferol treatments raises questions about the biological importance of this observation...
  10. ncbi Vitamin D2 is much less effective than vitamin D3 in humans
    Laura A G Armas
    Creighton University, 601 North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA
    J Clin Endocrinol Metab 89:5387-91. 2004
    ..5:1.Vitamin D(2) potency is less than one third that of vitamin D(3). Physicians resorting to use of vitamin D(2) should be aware of its markedly lower potency and shorter duration of action relative to vitamin D(3)...
  11. ncbi The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency
    P Leventis
    Department of Rheumatology, St George s Healthcare NHS Trust, London, UK
    Scand J Rheumatol 38:149-53. 2009
    ..To investigate the practicality and tolerability of high-dose intramuscular (i.m.) vitamin D2 or oral vitamin D3 replacement in vitamin D-insufficient patients, and to evaluate the biochemical efficacy of each formulation...
  12. ncbi Rapid correction of low vitamin D status in nursing home residents
    R Przybelski
    University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI 53705, USA
    Osteoporos Int 19:1621-8. 2008
    ..This prospective study finds that ergocalciferol 50,000 IU three times weekly for four weeks effectively and safely corrects vitamin D inadequacy in nursing home residents...
  13. ncbi Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D
    Michael F Holick
    Department of Medicine, Boston University School of Medicine, 715 Albany Street, M 1013, Boston, Massachusetts 02118, USA
    J Clin Endocrinol Metab 93:677-81. 2008
    ..Two reports suggested that vitamin D2 is less effective than vitamin D3 in maintaining vitamin D status...
  14. ncbi Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
    Stuart M Sprague
    Division of Nephrology Hypertension and Department of Medicine, Northwestern University Feinberg School of Medicine, Evanston, Illinois 60201, USA
    Kidney Int 63:1483-90. 2003
    ..A comparative study was undertaken in order to determine whether paricalcitol provides a therapeutic advantage to calcitriol...
  15. ncbi Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials
    Heike A Bischoff-Ferrari
    Department of Nutrition, Harvard School of Public Health, Boston, Mass 02115, USA
    JAMA 293:2257-64. 2005
    ..The role and dose of oral vitamin D supplementation in nonvertebral fracture prevention have not been well established...
  16. ncbi Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 8:2820-7. 2002
    ..Whereas the defined maximum tolerated dose was not reached, the recommended Phase II dose was 12.5 microg/day given continuously...
  17. ncbi Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines
    Laurent Brard
    Department of Obstetrics and Gynecology, Alpert Medical School, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 123:370-8. 2011
    ..This study was designed to evaluate a novel non-hypercalcemic vitamin-D derivative (MT19c) and its anticancer effects in cultured ovarian cancer cell model...
  18. ncbi Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
    Ashley Stuckey
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants7 Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 11:308. 2011
    ..In this study we identify genes and gene networks important for the efficacy of a pre-clinical anti-tumor therapeutic, MT19c...
  19. ncbi The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer
    T C Chen
    Vitamin D, Skin and Bone Research Laboratory, Boston University Medical Center, Massachusetts 02118, USA
    Clin Cancer Res 6:901-8. 2000
    ..Both drugs are approved for human use and may be good candidates for human clinical trials in prostate cancer...
  20. ncbi Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol
    S M Sprague
    Department of Medicine, Division of Nephrology Hypertension, Northwestern University Medical School, Chicago and Evanston, IL, USA
    Am J Kidney Dis 38:S51-6. 2001
    ..0 mg/dL) was greater in those administered calcitriol compared with paricalcitol. In conclusion, our data suggest that paricalcitol reduces PTH levels more rapidly, with fewer episodes of hyperphosphatemia, than intravenous calcitriol...
  21. ncbi Comparative review of the pharmacokinetics of vitamin D analogues
    George R Bailie
    Albany College of Pharmacy, Albany, New York, USA
    Semin Dial 15:352-7. 2002
    ..More studies are warranted to determine the disposition of the vitamin D analogues, especially in selected populations such as pediatric and geriatric dialysis patients...
  22. ncbi The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets
    Tom D Thacher
    Department of Family Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 94:3314-21. 2009
    ..Children with calcium-deficiency rickets have high 1,25-dihydroxyvitamin D values...
  23. ncbi Early response to vitamin D2 in children with calcium deficiency rickets
    Tom D Thacher
    Department of Family Medicine, Jos University Teaching Hospital, University of Jos, Jos, Nigeria
    J Pediatr 149:840-4. 2006
    ..Assessment of vitamin D sufficiency in persons or communities may need to be adjusted for habitual dietary calcium intake...
  24. ncbi Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport
    Alex J Brown
    Renal Division, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Lab Clin Med 139:279-84. 2002
    ..In summary, the reduced calcemic and phosphatemic activities of 19-norD(2) can be attributed to lower potency in stimulating intestinal calcium and phosphate absorption...
  25. ncbi Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2
    F Llach
    Division of Nephrology, Newark Beth Israel Medical Center, NJ 07112, USA
    Am J Kidney Dis 32:S48-54. 1998
    ..These results show that paricalcitol safely and effectively reduces iPTH levels in hemodialysis patients with secondary HPT...
  26. ncbi Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols
    V Shalhoub
    Department of Metabolic Disorders, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Calcif Tissue Int 79:431-42. 2006
    ..In this study, exposure of BASMCs to phosphate and active vitamin D sterols induced calcification and changes in expression of genes associated with mineralized tissue...
  27. ncbi Impact of kidney bone disease and its management on survival of patients on dialysis
    Grace H Lee
    Department of Pharmacy, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Ren Nutr 17:38-44. 2007
    ..Because these associations may be secondary to bias by indication, randomized clinical trials are necessary to verify the findings of this and similar observational studies...
  28. ncbi Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy
    Xiaoyue Tan
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Am Soc Nephrol 17:3382-93. 2006
    ..These studies suggest that paricalcitol is able to ameliorate renal interstitial fibrosis in obstructive nephropathy, possibly by preserving tubular epithelial integrity through suppression of EMT...
  29. ncbi Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients
    Tilman B Drueke
    Am J Kidney Dis 47:1083; author reply 1083-4. 2006
  30. ncbi Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients
    Wacharee Seeherunvong
    Division of Pediatric Nephrology, Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Pediatr Nephrol 21:1434-9. 2006
    ..Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients...
  31. ncbi Differential effects of Vitamin D analogs on bone formation and resorption
    Masaki Nakane
    Abbott Laboratories, R4CM, AP52, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    J Steroid Biochem Mol Biol 98:72-7. 2006
    ....
  32. ncbi Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer
    Gary G Schwartz
    Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, and Nortwest Georgia Oncology Centers, Douglasville, USA
    Clin Cancer Res 11:8680-5. 2005
    ....
  33. ncbi Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women
    S R Mastaglia
    Seccion Osteopatias Medicas, Hospital de Clinicas, Universidad de Buenos Aires, Buenos Aires, Argentina
    Eur J Clin Nutr 60:681-7. 2006
    ..Assessment of the effectiveness and safety of high daily 125 microg (5,000 IU) or 250 microg (10,000IU) doses of vitamin D(2) during 3 months, in rapidly obtaining adequate 25 hydroxyvitamin D (25OHD) levels...
  34. ncbi A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4
    Hanna Abboud
    University of Texas Health Science Center, San Antonio, Texas, USA
    Am J Nephrol 26:105-14. 2006
    ..Moreover, the QD regimen had no significant effect on hypercalcemia, hyperphosphatemia or Ca x P product as compared with placebo or intermittent dosing...
  35. ncbi Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease
    Steven Cheng
    Renal Division, Washington University School of Medicine, St Louis, MO 63110-1093, USA
    Expert Opin Pharmacother 7:617-21. 2006
    ..Paricalcitol also compares favourably to other oral vitamin D analogues, effectively decreasing parathyroid secretion with less hypercalcaemia and hypercalciuria than other agents...
  36. ncbi The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats
    I Lopez
    Department of Medicina y Cirugia Animal, Universidad de Cordoba, Cordoba, Spain
    Kidney Int 73:300-7. 2008
    ..When used in combination with paricalcitol, AMG 641 provided excellent control of secondary hyperparathyroidism and prevented mortality associated with the use of vitamin D derivatives without causing tissue calcification...
  37. ncbi Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients
    H E Joist
    Renal Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
    Clin Nephrol 65:335-41. 2006
    ....
  38. ncbi Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease
    Anna L Zisman
    Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, Ill 60201, USA
    Am J Nephrol 27:36-43. 2007
    ..The goal of this analysis, therefore, was to determine the effect of ergocalciferol treatment on plasma PTH concentrations in vitamin D-deficient patients with stage 3 and stage 4 CKD...
  39. ncbi Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol
    J M Repo
    Medical School, University of Tampere, Tampere, Finland
    Kidney Int 72:977-84. 2007
    ..Possible explanations are that aggravated perivascular fibrosis after paricalcitol in renal insufficiency may be due to further suppression of calcitriol, or to a direct effect of the vitamin D analog...
  40. ncbi [Vitamine D in patients with osteoporosis: sufficient or necessary?]
    Serge Ferrari
    Service des maladies osseuses Centre collaborateur de I OMS pour la prevention de l ostéoporose, Département de réhabilitation et gériatrie, HUG, 1211 Geneve
    Rev Med Suisse 3:1515-6, 1518-20. 2007
    ..Moreover, the risk of osteoporosis and of fragility fractures may be influenced by genetic variation in the vitamin D receptor (VDR)...
  41. ncbi Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate
    Glenn M Chertow
    Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, USA
    Clin J Am Soc Nephrol 1:305-12. 2006
    ..The long-term effects of this treatment regimen on clinical outcomes should be tested prospectively...
  42. ncbi Vitamin D and kidney disease
    Wisam Al-Badr
    Division of Nephrology, Saint Louis University, St Louis, Missouri, USA
    Clin J Am Soc Nephrol 3:1555-60. 2008
    ..Further work is required to define the mechanisms involved and to examine the effects of vitamin D therapy on outcomes in randomized, controlled trials...
  43. ncbi Vitamin D receptor activators can protect against vascular calcification
    Suresh Mathew
    Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Am Soc Nephrol 19:1509-19. 2008
    ..We conclude that low, clinically relevant dosages of calcitriol and paricalcitol may protect against CKD-stimulated vascular calcification...
  44. ncbi Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease
    Marie Claude Monier Faugere
    Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington, KY 40536 0084, USA
    Clin J Am Soc Nephrol 2:1255-60. 2007
    ....
  45. ncbi Relationship between vitamin D and muscle size and strength in patients on hemodialysis
    Patricia L Gordon
    Department of Physiological Nursing, School of Nursing, University of California at San Francisco, 2 Koret Way, San Francisco, CA 94143, USA
    J Ren Nutr 17:397-407. 2007
    ....
  46. ncbi Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease
    Dennis L Andress
    University of Washington School of Medicine, Seattle, Washington, USA
    Endocr Pract 14:18-27. 2008
    ..To review approved treatment options for secondary hyperparathyroidism (SHPT) in patients with stages 3 and 4 chronic kidney disease (CKD)...
  47. ncbi Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment
    Melanie S Joy
    School of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center, Univerisity of North Carolina, Chapel Hill, NC 27599 7155, USA
    J Manag Care Pharm 13:397-411. 2007
    ..The number of patients who will be identified and prescribed therapies for complications such as secondary hyperparathyroidism (SHPT) is greater than initially proposed...
  48. ncbi Differential effects of vitamin D receptor activators on vascular calcification in uremic rats
    M Mizobuchi
    Renal Division, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Kidney Int 72:709-15. 2007
    ..Hence, different VDRAs have different effects on vascular calcification in uremic rats. The effects are independent of the serum calcium-phosphate product suggesting independent mechanisms...
  49. ncbi Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients
    Debra Blair
    Fresenius Medical Care, Western Massachusetts Kidney Center, Springfield, Massachusetts 01003, USA
    J Ren Nutr 18:375-82. 2008
    ....
  50. ncbi Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs
    Diego Brancaccio
    Chair of Nephrology, University of Milan, Ospedale San Paolo, Milan Italy
    J Nephrol 20:3-9. 2007
    ..This review will also elucidate the possible role of paricalcitol - a new vitamin D analog - in conditioning morbidity and mortality of patients on renal replacement therapy (RRT)...
  51. ncbi Differential effects of vitamin D analogs on vascular calcification
    Anna Cardus
    Department of Medicine, University of Lleida, Lleida, Spain
    J Bone Miner Res 22:860-6. 2007
    ..Calcitriol, but not paricalcitol, increased VSMC calcification in vitro and in vivo independently of calcium and phosphate levels. This increase in calcification was parallel to an increase in the RANKL/OPG ratio...
  52. ncbi Vitamin D in health and disease
    Robert P Heaney
    Creighton University, Omaha, NE 68131, USA
    Clin J Am Soc Nephrol 3:1535-41. 2008
    ..Recent data indicate that cholecalciferol (vitamin D(3)) is substantially more potent than ergocalciferol (vitamin D(2)) and that the safe upper intake level for vitamin D(3) is 10,000 IU/d...
  53. ncbi Vascular calcification in chronic kidney failure: role of vitamin D receptor
    J Ruth Wu-Wong
    Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064, USA
    Curr Opin Investig Drugs 8:237-47. 2007
    ....
  54. ncbi Survival differences between activated injectable vitamin D2 and D3 analogs
    K Kalantar-Zadeh
    Kidney Int 71:827; author reply 827-8. 2007
  55. ncbi Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy
    Frank A Gesek
    Millennium CME Institute, Inc, Hampton, NH, USA
    Nephrol Nurs J 35:5S-22S; quiz 23S. 2008
    ..Vitamin D deficiency is associated with cardiovascular disease and contributes to the high morbidity and mortality in patients with CKD...
  56. ncbi Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD
    Ziyad Al-Aly
    Division of Nephrology, Saint Louis Veterans Affairs Medical Center, St Louis, MO 63106, USA
    Am J Kidney Dis 50:59-68. 2007
    ..The effect of ergocalciferol administration on serum 25-hydroxyvitamin D and plasma intact parathyroid hormone (PTH) levels in these patients is not known...
  57. ncbi Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism
    Mario Cozzolino
    University of Milan, S Paolo Hospital, Renal Division, Via A Di Rudini, 8 20142, Milan, Italy
    Expert Opin Pharmacother 9:947-54. 2008
    ..Classically, SHPT is induced by hypocalcemia, hyperphosphatemia, and calcitriol deficiency, that cause not only renal osteodystrophy but also systemic toxicity, particularly cardiovascular disease...
  58. ncbi [New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics]
    J Bover
    , , Barcelona
    Nefrologia 25:109-16. 2005
    ..The future treatment of SHP will probably require the independent management of calcium, phosphorus, vitamin D and PTH. Thus, low-dose combined treatments with selective drugs may prove more effective than sequential therapies...
  59. ncbi Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells
    J Ruth Wu-Wong
    J Thromb Haemost 3:1545-6. 2005
  60. ncbi Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up
    Suhail B Shuja
    Division of Nephrology, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA
    Adv Perit Dial 19:231-5. 2003
    ..To control severe secondary hyperparathyroidism in these patients, dietary and medication compliance may need to be supplemented with more effective non-calcium phosphate binders or calcimimetic agents, or both...
  61. ncbi Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
    Jack W Coburn
    West Los Angeles Veterans Affairs Healthcare Center, Los Angeles, CA 90073, USA
    Am J Kidney Dis 43:877-90. 2004
    ..We evaluated doxercalciferol (1alpha-hydroxyvitamin D2) as an alternative therapy in a randomized, double-blinded, placebo-controlled, multicenter trial...
  62. ncbi [The trend in the development of the active vitamin D3 and its analogues]
    Naoko Miwa
    Department of Medicine, Kidney Center, Tokyo Women's Medical University
    Nippon Rinsho 62:364-7. 2004
  63. ncbi Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis
    Yujiro Kida
    N Engl J Med 349:1971-2; author reply 1971-2. 2003
  64. ncbi Paricalcitol as compared with calcitriol in patients undergoing hemodialysis
    Tilman B Drueke
    N Engl J Med 349:496-9. 2003
  65. ncbi Effects of vitamin D compounds on renal and intestinal Ca2+ transport proteins in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice
    Joost G J Hoenderop
    Department of Physiology, Nijmegen Centre for Molecular Life Sciences, University Medical Centre Nijmegen, The Netherlands
    Kidney Int 66:1082-9. 2004
    ..This study indicates that Ca(2+) transport proteins, including TRPV5 and TRPV6, are differentially up-regulated by vitamin D compounds...
  66. ncbi Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
    Ming Teng
    Fresenius Medical Care North America, Lexington, Mass, USA
    N Engl J Med 349:446-56. 2003
    ..A prospective, randomized study is critical to confirm these findings...
  67. ncbi Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients
    A Barton Pai
    College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Int J Artif Organs 26:484-90. 2003
    ..CONCLUSION: During the study, PTH was not adequately suppressed by paricalcitol. This was primarily attributed to withholding paricalcitol doses due to elevated serum calcium and Ca x P levels...
  68. ncbi [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient]
    D Brancaccio
    Divisione di Nefrologia e Dialisi, Ospedale San Paolo, Milano, Italy
    G Ital Nefrol 20:S12-6. 2003
    ..In conclusion, a combined use of non calcemic phosphate binders, new vitamin D analogs and calcimimetics should be seriously considered to further improve the already known therapy of secondary hyperparathyroidism in ESRD patients...
  69. ncbi Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone
    Robert A Upton
    Department of Biopharmaceutical Sciences, University of California, San Francisco, CA, USA
    Nephrol Dial Transplant 18:750-8. 2003
    ..This is the first detailed pharmacokinetic report published on the administration of doxercalciferol [1alpha(OH)D(2)] recently introduced to treat secondary hyperparathyroidism...
  70. ncbi Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients
    M E Staniforth
    Department of Internal Medicine, Renal Division, Washington University School of Medicine, St. Louis, MO 63110, USA
    Clin Nephrol 63:454-60. 2005
    ..Less frequent dosing may better allocate nursing time and potentially benefit other patient populations with CKD and ESRD...
  71. ncbi Activated injectable vitamin D and hemodialysis survival: a historical cohort study
    Ming Teng
    Fresenius Medical Care North America, Lexington, Massachusetts, USA
    J Am Soc Nephrol 16:1115-25. 2005
    ..Randomized clinical trials would permit definitive conclusions...
  72. ncbi Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients
    Daniel W Coyne
    Department of Internal Medicine, Renal Division, and the Chromalloy American Kidney Center at Washington University School of Medicine, St Louis, MO, USA
    Am J Kidney Dis 40:1283-8. 2002
    ..The vitamin D analogue 19-nor-1,25(OH)2-vitamin D2 (19-Nor) causes less hypercalcemia and elevated Ca x P, whereas it still suppresses PTH in rats...
  73. ncbi Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    J Ruth Wu-Wong
    Abbott Laboratories, R4CM Building AP52, 200 Abbott Park Road, Abbott Park, IL 60064, USA
    Curr Opin Investig Drugs 6:245-54. 2005
    ..This review discusses recent data regarding the role of vitamin D and its analogs in the CVD associated with CKD...
  74. ncbi Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis
    Giacomo Colussi
    N Engl J Med 349:1971-2; author reply 1971-2. 2003
  75. ncbi Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings
    Deborah G Dobrez
    Center for Outcomes Research and Education, Evanston Northwestern Healthcare, Evanston, and Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL USA
    Nephrol Dial Transplant 19:1174-81. 2004
    ..Pharmacologic parenteral vitamin D administration is used to correct these abnormalities; however, the relationship between vitamin D therapies and hospitalizations has never been addressed...
  76. ncbi Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (review)
    K Wikvall
    Division of Biochemistry, Department of Pharmaceutical Biosciences, University of Uppsala, P O Box 578, S 751 23 Uppsala, Sweden
    Int J Mol Med 7:201-9. 2001
    ..The relative importance and regulation of the different renal 1alpha-hydroxylases in the bioactivation of vitamin D3 under normal and pathological conditions will be subject for future studies...
  77. ncbi Effect of Vitamin D on falls: a meta-analysis
    Heike A Bischoff-Ferrari
    Division of Aging, Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
    JAMA 291:1999-2006. 2004
    ..Falls among elderly individuals occur frequently, increase with age, and lead to substantial morbidity and mortality. The role of vitamin D in preventing falls among elderly people has not been well established...
  78. ncbi Treatment of adult hypophosphatasia with teriparatide
    Pauline M Camacho
    Division of Endocrinology and Metabolism, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Endocr Pract 14:204-8. 2008
    ..To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment...
  79. ncbi Measurement of 25-OH-vitamin D in human serum using liquid chromatography tandem-mass spectrometry with comparison to radioimmunoassay and automated immunoassay
    Johannes M W Van Den Ouweland
    Department of Clinical Chemistry, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 878:1163-8. 2010
    ..90; average bias 1.61 nmol/L), the Roche ECLIA considerably disagreed (r(2)=0.58; bias 10.13 nmol/L). This LC-MS/MS method is reliable and robust for the measurement of both 25-OH vitamin D3 and 25-OH vitamin D2 in human serum...
  80. ncbi Nutritional interventions related to bone turnover in European space missions and simulation models
    Martina Heer
    Institute of Aerospace Medicine, German Aerospace Center, DLR, Cologne, Germany
    Nutrition 18:853-6. 2002
    ..During and after supplementation, bone formation markers increased significantly during this part of the mission. Therefore, vitamin K seems to play a significant role in bone turnover during space flight...
  81. ncbi Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method
    J M Mata-Granados
    Department of I D i, Sanyres Group, University of Cordoba, Mineral Metabolism Unit, Hospital Reina Sofia, E 14004 Cordoba, Spain
    J Steroid Biochem Mol Biol 121:452-5. 2010
    ..Both treatments could produce an improvement in the general health and probably a reduction in overall mortality risk of the critically ill patients...
  82. ncbi Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle
    Charles J Glueck
    Cholesterol and Metabolism Center, Jewish Hospital of Cincinnati, ABC Building, 3200 Burnet Ave, Cincinnati, OH 45229, USA
    Med Hypotheses 77:658-61. 2011
    ....
  83. ncbi Stability in the rumen and effect on plasma status of single oral doses of vitamin D and vitamin E in high-yielding dairy cows
    L Hymøller
    Department of Animal Health and Bioscience, Aarhus University, Faculty of Agricultural Sciences, DK 8830 Tjele, Denmark
    J Dairy Sci 93:5748-57. 2010
    ..The limited plasma response after a single dose of α-tocopheryl acetate led to the conclusion that oral single dose therapy with all-rac-α-tocopheryl acetate is of limited physiological value...
  84. ncbi Meals and dephytinization affect calcium and zinc absorption in Nigerian children with rickets
    Tom D Thacher
    Department of Family Medicine, Mayo Clinic, Rochester, MN 55903, USA
    J Nutr 139:926-32. 2009
    ..Enzymatic dephytinization increased zinc absorption. Multiple strategies may be required to optimize calcium and zinc absorption in deficient populations...
  85. ncbi [Effect of over-expression of sterol C-22 desaturase on ergosterol production in yeast strains]
    Peng li Cai
    Institute of Microbiology of Chinese Academy of Sciences, Beijing, 100080, China
    Wei Sheng Wu Xue Bao 47:274-9. 2007
    ..Under the optimal culture condition, ergosterol content in recombinant strain YS58 (pYPE5) was about 0.70-fold of that in the referring strain...
  86. ncbi Angiotensin-converting enzyme inhibitory and antioxidant activities of enzymatically synthesized phenolic and vitamin glycosides
    Rajachristu Einstein Charles
    Fermentation Technology and Bioengineering, Central Food Technological Research Institute, Council of Scientific and Industrial Research, Mysore 570 020, India
    Biotechnol Appl Biochem 52:177-84. 2009
    ..9+/-0.05 mM), 3-hydroxy-4-O-(beta-D-galactopyranosyl-(1'-->4)beta-D-glucopyranosyl)phenylalanine (0.9+/-0.05 mM), 20-O-(D-glucopyranosyl)ergocalciferol (0.9+/-0.05 mM) and dopamine-D-galactoside (0.93+/-0.05 mM)...
  87. ncbi Lambda light chain induced nephropathy: a rare cause of the Fanconi syndrome and severe osteomalacia
    K L Bate
    Departments of Medicine, Anatomical Pathology, Nephrology, and Laboratory Medicine, Royal Melbourne Hospital, Victoria, Australia
    Am J Kidney Dis 32:E3. 1998
    ..However, it is rare for the light chains to be of the lambda subtype. This may reflect differences in the physicochemical properties of kappa and lambda light chains...
  88. ncbi Minimizing bone abnormalities in children with renal failure
    Helena Ziolkowska
    Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland
    Paediatr Drugs 8:205-22. 2006
    ..In recent years, a number of new drugs have emerged that hold promise for a more effective treatment of bone lesions in CRF. This review describes the current approach to the diagnosis and treament of ROD...
  89. ncbi Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity
    Sean Carlton
    Stanford Hospital and Clinics, Stanford, California, USA
    Consult Pharm 25:171-7. 2010
    ..Pharmacists also should be familiar with possible toxic effects of vitamin D, particularly as public awareness of benefits continues to increase...
  90. ncbi Vitamin D ameliorates stress ligand expression elicited by free fatty acids in the hepatic stellate cell line LX-2
    Seyda Seydel
    University Hospital Essen Hufelandstr, Essen, Germany
    Turk J Gastroenterol 22:400-7. 2011
    ..The aim of this study was therefore to investigate the effect of vitamin D2 and free fatty acids on stress ligands and pro-fibrotic activity in LX-2 cells and human primary hepatic stellate cells...
  91. ncbi Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency
    Kun Zhu
    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    J Bone Miner Res 23:1343-8. 2008
    ..Vitamin D supplementation adds no extra short-term skeletal benefit to calcium citrate supplementation even in women with vitamin D insufficiency...
  92. ncbi Side-chain-modified analogs of calcitriol cause resistance of human HL-60 promyelocytic leukemia cells to drug-induced apoptosis
    Agnieszka Chrobak
    Department of Reproductive Immunology, Institute of Immunology and Experimental Therapy, ul R Weigla 12, 53 114 Wroclaw, Poland
    Steroids 70:19-27. 2005
    ..These results indicate the potential limitations of calcitriol analogs for treatment of leukemia...
  93. ncbi Evaluation of ergosterol and its esters in the pileus, gill, and stipe tissues of agaric fungi and their relative changes in the comminuted fungal tissues
    Jian Ping Yuan
    State Key Laboratory of Biocontrol Food Engineering Research Center of State Education Ministry, College of Life Sciences, Sun Yat Sen University, Guangzhou, People s Republic of China
    Appl Microbiol Biotechnol 80:459-65. 2008
    ..It is suggested that free ergosterol (not total ergosterol) should be used as a biomarker for fungal biomass...
  94. ncbi Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24-hydroxylase
    Mehrdad Rahmaniyan
    Department of Medicine, Medical University of South Carolina, Strom Thurmond Research Building, Charleston, SC 29425, USA
    Am J Physiol Endocrinol Metab 288:E753-60. 2005
    ..It is concluded that CYP2C11 is a male-specific hepatic microsomal vitamin D 25-hydroxylase that hydroxylates vitamin D2, vitamin D3, 1alphaOHD2, and 1alphaOHD3. CYP2C11 is also a vitamin D 24-hydroxylase...
  95. ncbi Determination of cholecalciferol (vitamin D3) in selected foods by liquid chromatography: NMKL collaborative study
    Anders Staffas
    Swedish National Food Administration, Box 622, SE 751 26 Uppsala, Sweden
    J AOAC Int 86:400-6. 2003
    ..2% (fish oil) and 7.4% (cooking oil), whereas the reproducibility relative standard deviation (RSD(R)) values varied between 6.8% (margarine) and 24% (cooking oil)...
  96. ncbi Hypovitaminosis D is common among pulmonary tuberculosis patients in Tanzania but is not explained by the acute phase response
    Henrik Friis
    Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark
    J Nutr 138:2474-80. 2008
    ..The health consequences of hypovitaminosis D in low-income equatorial populations, at risk for both infectious and chronic diseases, should be studied...
  97. ncbi Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats
    Chen Road Hung
    Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC
    Chin J Physiol 50:315-25. 2007
    ..Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats...
  98. ncbi Development and optimization of an LC-MS/MS-based method for simultaneous quantification of vitamin D2 , vitamin D3 , 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
    Jiri Adamec
    Bindley Bioscience Center, Purdue University, West Lafayette, IN, USA
    J Sep Sci 34:11-20. 2011
    ..9-111.2%. In summary, a sensitive and reproducible method is reported for simultaneous quantification of vitamin D(2) , vitamin D(3) , 25-hydroxyvitamin D(2) and 25-hydroxyvitamin D(3) molecules in biological samples...
  99. ncbi Exogenous versus endogenous recovery of 25-hydroxyvitamins D2 and D3 in human samples using high-performance liquid chromatography and the DiaSorin LIAISON Total-D Assay
    Ronald L Horst
    Heartland Assays Inc, 2325 North Loop Dr, Suite 6300, Ames, IA 50010, United States
    J Steroid Biochem Mol Biol 121:180-2. 2010
    ..Only endogenous 25(OH)D2 and/or 25(OH)D3 contained in human blood samples should be utilized for this purpose...
  100. ncbi Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays
    P Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Australia
    Ann Clin Biochem 43:23-30. 2006
    ..Lack of standardization of these methods has resulted in inter-method disagreement and challenged whether current assays recognize 25(OH)D2 and 25(OH)D3 equally...
  101. ncbi Bone disease in uremic patients: advances in PTH suppression
    Diego Brancaccio
    Nephrology and Dialysis Department, Ospedale San Paolo, Milan, Italy
    J Nephrol 15:S86-93. 2002
    ..A broader spectrum of therapeutic approaches will enable the nephrologist to individually tailor the treatment of secondary hyperparathyroidism...

Research Grants102 found, 100 shown here

  1. Ergocalciferol in ESRD Efficacy Safety and Biology
    Ravi Thadhani; Fiscal Year: 2009
    ..Our study is designed to determine safe and effective ways to raise vitamin D levels while monitoring effects on the immune system. ..
  2. REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY
    ISIDRO SALUSKY; Fiscal Year: 2000
    ..These studies will provide new information about tissue specific modifiers of cancellous bone formation and endochondral bone formation in children with renal osteodystrophy. ..
  3. REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY
    Isidro B Salusky; Fiscal Year: 2004
    ..The result of the study should provide new information on the regulation of bone formation and PTH by different vitamin D sterols in patients with 2-HPT. ..
  4. 2005 Bones & Teeth Gordon Conference
    Rene St Arnaud; Fiscal Year: 2005
    ..These funds, if granted, will aid immeasurably in allowing the Gordon Research Conference to fulfill its function to stimulate further creativity in bone, cartilage and tooth research. ..
  5. Evaluation of Vitamin D Requirements During Pregnancy
    Bruce Hollis; Fiscal Year: 2007
    ....
  6. Optimizing Vitamin D Treatment in HIV/AIDS: An RCT
    DOUGLAS THOMAS DIETERICH; Fiscal Year: 2010
    ..Our study will help physicians make evidence-based decisions about the most effective way to use vitamin D in their patients and enable the design of large multi-center trials in the future. ..
  7. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej Slominski; Fiscal Year: 2007
    ..6. Defining the effect of 7-DHP, its hydroxy and seco-derivatives and of vitamin D (modified or unmodified) on P450scc mediated pregnenolone production from cholesterol. ..
  8. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej Slominski; Fiscal Year: 2009
    ..6. Defining the effect of 7-DHP, its hydroxy and seco-derivatives and of vitamin D (modified or unmodified) on P450scc mediated pregnenolone production from cholesterol. ..
  9. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej T Slominski; Fiscal Year: 2010
    ..6. Defining the effect of 7-DHP, its hydroxy and seco-derivatives and of vitamin D (modified or unmodified) on P450scc mediated pregnenolone production from cholesterol. ..
  10. Ergocalciferol in ESRD Efficacy Safety and Biology
    Ravi Thadhani; Fiscal Year: 2010
    ..Our study is designed to determine safe and effective ways to raise vitamin D levels while monitoring effects on the immune system. ..
  11. VITAMIN K AND BONE TURNOVER IN POSTMENOPAUSAL WOMEN
    Neil Binkley; Fiscal Year: 2003
    ..abstract_text> ..
  12. Hypertension in Hemodialysis Patients
    Rajiv Agarwal; Fiscal Year: 2010
    ..We hypothesize that that volume control can improve BP and antihypertensive therapy can regress left ventricular hypertrophy in long-term hemodialysis patients. ..
  13. Hypertension in Hemodialysis Patients
    Rajiv Agarwal; Fiscal Year: 2007
    ..Evaluation of such strategies will improve BP control in hemodialysis patients and, in the long-term, provide cardiovascular protection. ..
  14. Pathobiology of Kidney Disease: Role of Iron
    Rajiv Agarwal; Fiscal Year: 2007
    ..Novelty and Health Relatedness of the Project: This proposal will provide translational data on the role of intravenous iron to progression of kidney disease in patients with CKD. ..
  15. BONY EFFECTS OF TRANSIENT NONSKELETAL ILLNESS
    Robert Heaney; Fiscal Year: 2001
    ....
  16. Bone-Sparing by Ca Salts With & Without Extra Phosphorus
    Robert Heaney; Fiscal Year: 2006
    ..abstract_text> ..
  17. Molecular Biology of Retinoblastoma
    Daniel Albert; Fiscal Year: 2006
    ..Lastly the potency of the 19-nor compounds wil be compared to standard chemotherapy and their possible synergistic effect in multi-drug treatment established. ..
  18. Anti-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2007
    ....
  19. MOLECULAR BIOLOGY OF RETINOBLASTOMA AND UYEAL MELANOMA
    Daniel Albert; Fiscal Year: 1993
    ..In addition we have described the inhibition of retinoblastoma growth by vitamin D compounds and sodium butyrate and we will continue to study potential therapeutic strategies in the transgenic mouse model of retinoblastoma...
  20. MOLECULAR BIOLOGY OF RETINOBLASTOMA AND UVEAL MELANOMA
    Daniel Albert; Fiscal Year: 2000
    ..5. We will characterize pigmented tumors developing in the eyes of mice expressing SV40-T antigen (SV40-Tag) under the control of the mouse tyrosinase gene, and establish the relevance of these mice as a model for human uveal melanoma. ..
  21. THE PHOTOBIOLOGY OF VITAMIN D3
    Michael Holick; Fiscal Year: 1993
    ....
  22. Establishing the Vitamin D Requirements During Lactation
    Bruce Hollis; Fiscal Year: 2009
    ..The findings of this study will generate important new information for health care professionals and policy makers with regard to vitamin D requirements and the potential benefit to both mother and infant. ..
  23. Regulation of Bone Mineralization in Renal Osteodystrophy
    ISIDRO BENJAMIN SALUSKY; Fiscal Year: 2010
    ..Current evidence indicates that severe bone disease and growth retardation are the main long-term consequences of chronic kidney disease since childhood. ..
  24. Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
    Sharon M Moe; Fiscal Year: 2010
    ..Both of these problems may be linked. The purpose of this study is to determine if a commonly used group of drugs, bisphosphonates, may help both bone and heart/blood vessel disease and determine the mechanism the drugs work. ..
  25. Establishing the Vitamin D Requirements During Lactation
    Bruce Hollis; Fiscal Year: 2009
    ..The findings of this study will generate important new information for health care professionals and policy makers with regard to vitamin D requirements and the potential benefit to both mother and infant. ..
  26. Musculoskeletal Disorder in Dialysis Patients
    Sharon Moe; Fiscal Year: 2007
    ..These studies, Dr. Moe, and the strong clinical research support at Indiana Unviersity provide an excellent training environment for the development of future investigators in patient oriented research. ..
  27. ROLE OF PARATHYROID HORMONE IN RENAL OSTEODYSTROPHY
    Isidro B Salusky; Fiscal Year: 2009
    ..The results of the study should provide new information on the relationship between PTH and bone formation in CKD and they are likely to have important implications for the diagnosis and treatment of renal osteodystrophy. ..
  28. THE MOLECULAR BIOLOGY OF RETINOBLASTOMA
    Daniel Albert; Fiscal Year: 2005
    ..2d) Determine whether I a-hydroxy-D2 and 16,23 -D3 inhibit angiogenesis in a transgenic mouse model. These studies will complete the pre-clinical investigation of the efficacy of vitamin D analogs for human treatment. ..
  29. Establishing the Vitamin D Requirements During Lactation
    Bruce Hollis; Fiscal Year: 2007
    ..The findings of this study will generate important new information for health care professionals and policy makers with regard to vitamin D requirements and the potential benefit to both mother and infant. ..
  30. Regulation of Bone Mineralization in Renal Osteodystrophy
    Isidro B Salusky; Fiscal Year: 2009
    ..Current evidence indicates that severe bone disease and growth retardation are the main long-term consequences of chronic kidney disease since childhood. ..
  31. Examining Racial and Cardiovascular Paradoxes in Chronic Kidney Disease
    Kamyar Kalantar Zadeh; Fiscal Year: 2009
    ..to developing new treatment targets beyond traditional (Framingham) CV risk factors to improve poor outcomes in these 2 patient populations and maybe in geriatric populations or those with chronic disease states and similar paradoxes ..
  32. FREEDOM - Frequent Dialysis Outcomes & Markers Study
    Glenn Chertow; Fiscal Year: 2006
    ..We are committed to working cooperatively and constructively with the other CCC and Data Analysis Coordinating Center-regardless of the final agreed-upon protocol. ..
  33. Nutritional/Inflammatory Evaluation of Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2005
    ....